The increase in operating expenses for Cardiff Oncology in Q4 2024 was primarily driven by clinical programs and outside service costs related to the development of their lead drug candidate, onvansertib1.
The company's ongoing randomized Phase II trial of onvansertib for first-line RAS-mutated metastatic colorectal cancer (mCRC) also contributed to the surge in expenses. This trial has shown promising initial data, with a 64% objective response rate at the 30 mg dose, which further underscores the need for continued investment in its development23.